BAXTER INTERNATIONAL INC acquires Caelyx and Doxil rights (ex-US, from a subsidiary of Johnson & Johnson)

BAXTER INTERNATIONAL INC acquired Caelyx and Doxil rights (ex-US, from a subsidiary of Johnson & Johnson) for approximately $325 million in cash, a transaction completed in February 2021, structured as all cash. The deal was a Asset purchase.

Caelyx and Doxil rights (ex-US, from a subsidiary of Johnson & Johnson) operates in Oncology pharmaceuticals, is based in Rights for territories outside the United States (acquired from a Johnson & Johnson subsidiary). Caelyx and Doxil are the branded versions of liposomal doxorubicin, a chemotherapy medicine used to treat various types of cancer; Baxter acquired the rights for specified territories outside the U.S. from a subsidiary of Johnson & Johnson (having previously acquired the U.S. rights to the product in 2019).

Expands Baxter's pharmaceuticals portfolio with an established branded oncology product, completing its global rights to liposomal doxorubicin.

Completed Baxter's global rights to an established branded oncology product (liposomal doxorubicin). Integrated into Baxter's pharmaceuticals business

On February 17, 2021, we acquired the rights to Caelyx and Doxil, the branded versions of liposomal doxorubicin, from a subsidiary of Johnson & Johnson for specified territories outside of the U.S for approximately $325 million in cash. We previously acquired the U.S. rights to this product in 2019.Baxter FY2021 10-K, Acquisitions note

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.